SURPASS-CVOT: Tirzepatide Cardiovascular Outcomes Research

SURPASS-CVOT Overview

The SURPASS-CVOT trial (N=13,884) was a randomized, active-controlled cardiovascular outcomes trial comparing tirzepatide to dulaglutide (a GLP-1 receptor agonist) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.

Primary Endpoint

MACE-3 (cardiovascular death, non-fatal MI, non-fatal stroke):

• Tirzepatide: HR 0.85 (95% CI 0.80–0.90) vs. dulaglutide
• 15% relative risk reduction vs. an active GLP-1 comparator
• Non-inferiority confirmed; superiority demonstrated

Secondary Endpoints

Mechanistic Discussion

The SURPASS-CVOT results raise important mechanistic questions:

GIP receptor contribution to CV protection:

• GIPR is expressed in cardiomyocytes and endothelium
• Preclinical models show GIPR agonism reduces cardiac remodeling post-MI
• GIP may have direct anti-inflammatory effects on vascular endothelium

Incremental benefit over GLP-1 RA: The 15% additional CV risk reduction over dulaglutide (itself cardioprotective) suggests that GIP receptor activation contributes meaningfully to cardiovascular protection independent of glycemic and weight effects.

Context Within the Cardiometabolic Pipeline

SURPASS-CVOT positions tirzepatide as having the most robust cardiovascular outcomes data of any incretin-based compound, surpassing even the GLP-1 RA class effect demonstrated in LEADER (liraglutide) and SUSTAIN-6 (semaglutide).

Research Takeaways

For researchers investigating cardiovascular metabolic biology, tirzepatide offers a unique tool to study combined GLP-1R + GIPR effects on cardiac and vascular endpoints. The SURPASS-CVOT data provides a clinical anchor for interpreting preclinical mechanistic findings.

Research-grade tirzepatide available through Apollo Peptide Sciences for laboratory use.